Cross-industry partnerships are shaping new systems that support GLP-1 users before, during, and after treatment
It is designed to simultaneously activate GLP-1, GIP, and glucagon receptors, offering a comprehensive approach to studying weight regulation, metabolic efficiency, and energy balance
The SUSTAIN-6 trial investigated whether once-weekly semaglutide (0.5 mg or 1.0 mg) could reduce CVD risk in patients aged 50 or older with T2D
Personalized Treatment for Every Child No two children have the same metabolism, medical history, or treatment goals
This tri agonist architecture allows researchers to investigate how simultaneous activation of incretin and glucagon pathways alters intracellular signaling processes such as cyclic AMP generation, kinase activation, and coordinated metabolic pathway regulation across tissues